# Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

> **NCT07481604** · PHASE2 · NOT_YET_RECRUITING · sponsor: **CHA Vaccine Institute Co., Ltd.** · enrollment: 135 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Shingrix
- **BIOLOGICAL:** CVI-VZV-001

## Key facts

- **NCT ID:** NCT07481604
- **Lead sponsor:** CHA Vaccine Institute Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481604, "Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07481604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*